Cabinet Office to Support Overseas Expansion of Companies Developing Drugs to Treat Rare, Intractable Diseases

The Cabinet Office will this year begin supporting overseas expansion by startups and midsize companies developing drugs to treat intractable or rare diseases, in an effort to strengthen the nation’s pharmaceutical development capabilities. It will subsidize the costs of participating in simultaneous domestic and foreign clinical trials to confirm the efficacy of such drugs.